Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q3 EPS of $0.02, $0.09 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $9.3 million versus the consensus estimate of $8.61 million.

At September 30, 2020, Cumberland had $96.0 million in total assets including $26.6 million in cash and cash equivalents. Total liabilities were $48.2 million, including $17.0 million outstanding on the Company\'s revolving line of credit, resulting in total shareholders\' equity of $47.9 million.

For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.